YB4P Stock Overview
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Savara Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$5.05 |
| 52 Week Low | US$1.60 |
| Beta | 0.70 |
| 1 Month Change | 1.36% |
| 3 Month Change | -2.61% |
| 1 Year Change | 180.00% |
| 3 Year Change | 174.85% |
| 5 Year Change | -51.97% |
| Change since IPO | -42.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| YB4P | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.1% | -5.1% | -2.0% |
| 1Y | 180.0% | -21.1% | -0.3% |
Return vs Industry: YB4P exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: YB4P exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| YB4P volatility | |
|---|---|
| YB4P Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YB4P has not had significant price volatility in the past 3 months.
Volatility Over Time: YB4P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 37 | Matt Pauls | www.savarapharma.com |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc. Fundamentals Summary
| YB4P fundamental statistics | |
|---|---|
| Market cap | €623.95m |
| Earnings (TTM) | -€51.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.9x
P/E RatioIs YB4P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YB4P income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$44.26m |
| Gross Profit | -US$44.26m |
| Other Expenses | US$10.44m |
| Earnings | -US$54.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.8% |
How did YB4P perform over the long term?
See historical performance and comparison